The upgrade in the price target by a reputable analyst like Jessica Fye from JP Morgan is a strong positive signal for Vertex Pharmaceuticals. It suggests confidence in the company's future performance and growth prospects, likely leading to increased investor interest and potentially a rise in stock price in the short term.